Breast cancer vaccination outcome with

In another study involving patients with metastatic breast, colorectal and ovarian cancer, increased anti-sTn titers were correlated with better survival. Even if before treatment, elevated titers of antibodies against the mucin MUC1, were correlated with a poor response to immunotherapy, CTL precursors to the MUC1 were detected in carcinoma patients [208], A vaccine using 10 pg/ml MUC1-KLH mixed with Detox was injected s.c. in breast cancer patients treated with cyclophosphamide. A weak antibody response, and an ex vivo CTL response against HLA-matched adenocarcinoma cell lines were seen. No correlation with the clinical outcome was available [209],... 

Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant... 

Among breast cancer patients alone, the IgG antibody titer to STn was statistically signiftcantly higher after vaccination with the second formulation compared to the first formulation (p=.009). The IgG antibody titer to OSM was marginally statistically significant higher after vaccination with the second formulation compared to the first formulation (p=.08) and were thus used to evaluate outcome. 

Since breast cancer patients were the largest group of patients treated with the two different formulations of Theratope vaccine, we. focused again on evaluating the outcome after vaccination as a function of in vitro immunological responses. Fifty-three patients were available for this analysis. 

Holmberg L. A. Oparin D. V. Gooley T. et al. Clinical outcome of breast and ovarian cancer patients treated with high dose chemotherapy, autologous stem cell rescue and Theratope vaccine STn-KLH cancer vaccine. Bone Marrow Transpl 2000,25, 1233-1241. 

---